Trial Title:
NeoAdj. Therapy Comparing Sacituzumab Govitecan (SG) vs. SG+Pembrolizumab in Low-risk, Triple-neg. EBC (ADAPT-TN-III)
NCT ID:
NCT06081244
Condition:
Triple Negative Breast Cancer
Conditions: Official terms:
Breast Neoplasms
Triple Negative Breast Neoplasms
Pembrolizumab
Sacituzumab govitecan
Conditions: Keywords:
TNBC
Early breast cancer
Sacituzumab govitecan
pembrolizumab
chemotherapy
low recurrence risk
Study type:
Interventional
Study phase:
Phase 2
Overall status:
Not yet recruiting
Study design:
Allocation:
Randomized
Intervention model:
Parallel Assignment
Intervention model description:
This is a multicentre, interventional, prospective, two-arm, randomised, open-label,
neoadjuvant, phase-II-trial evaluating the efficacy and safety of SG alone vs. SG+PEM in
low-risk early TNBC in pre- and postmenopausal women.
Primary purpose:
Treatment
Masking:
None (Open Label)
Masking description:
Open Label.
Intervention:
Intervention type:
Drug
Intervention name:
Sacituzumab govitecan
Description:
10 mg/kg twice on Days 1 and 8 of a continuous 21-day treatment cycle
Arm group label:
Neoadjuvant treatment: 12 weeks (4 cycles) SG i.v.
Arm group label:
Neoadjuvant treatment: 12 weeks (4 cycles) SG+PEM i.v.
Other name:
Trodelvy
Intervention type:
Drug
Intervention name:
Pembrolizumab
Description:
200 mg every 3 weeks (q3w)
Arm group label:
Neoadjuvant treatment: 12 weeks (4 cycles) SG+PEM i.v.
Other name:
Keytruda
Summary:
TNBC is known for poor prognosis, aggressive patterns of disease, and significant
molecular heterogeneity. (Neo)adjuvant chemotherapy (NACT) is standard of care in all
node-positive and in node-negative patients with a tumour size >5 mm according to current
National Comprehensive Cancer Network (NCCN) guidelines. However, TNBC patients with
lower stage disease do clearly have a better prognosis compared to more advanced stages.
Patients with stage I-II node-negative disease have 3-5 year iDFS rates of 80-90% (with
majority of relapses within the first three years) as shown in several trials.Although
survival results appear much better in the lower vs. higher stages, there is a high
clinical need in this most common group of TNBC patients in Western Europe and USA.
Detailed description:
About 15% of breast cancers lack both, expression of ER and PR receptors, and
amplification/over-expression of HER2 receptors, and are thus described as triple
negative breast cancer (TNBC). TNBC is known for poor prognosis, aggressive patterns of
disease, and significant molecular heterogeneity. (Neo)adjuvant chemotherapy (NACT) is
standard of care in all node-positive and in node-negative patients with a tumour size >5
mm according to current National Comprehensive Cancer Network (NCCN) guidelines. However,
TNBC patients with lower stage disease do clearly have a better prognosis compared to
more advanced stages. Patients with stage I-II node-negative disease have 3-5 year iDFS
rates of 80-90% (with majority of relapses within the first three years) as shown in
several trials. Our own results from the PlanB- and ADAPT-trials, and pooled analysis
with SUCCESS C-trials show 3-year iDFS of 86-90% in node-negative TNBC with a tumour size
< 3 cm. Although survival results appear much better in the lower vs. higher stages,
there is a high clinical need in this most common group of TNBC patients in Western
Europe and USA.
In the neoadjuvant setting, it has been shown that the prognosis of patients with TNBC is
strongly dependent on their response to NACT: Patients achieving pathological complete
response (pCR), or a near pCR (an excellent response after NACT (residual cancer burden
(RCB) score 0-1), in some studies do have an excellent prognosis that is not
significantly different from that observed in other breast cancer subtypes. However,
patients with a less responsive disease (i.e., with RCB Score 2-3) suffer from a
significantly worse prognosis compared to non-TNBC.
Chemotherapy in TNBC The optimal chemotherapy regimen for patients with TNBC remains to
be identified. Standard anthracycline-taxane (A/T)-based NACT combinations render pCR
rates between 25-50%. However, the survival impact of anthracyclines remains
controversial due to conflicting results of different randomized trials. Adding
carboplatin (carbo) to A/T-containing poly-NACT or use of dose-intensified poly-NACT
significantly increases pCR-rates up to 49-60% in mostly stage II-III disease with
conflicting survival results and higher toxicity. Hence, use of pragmatic
taxane-carboplatin anthracycline-free combinations appears as an effective treatment
option in TNBC instead of further treatment escalation. This probably is independent of
the germline BRCA (gBRCA) status, due to its general chemo-predictive effect.
Unfortunately, no prospective phase-III-data are available so far. However, indirect
comparison between trials renders similar pCR rates in taxane-carboplatin based vs.
A/T+/-carbo-based regimens in early TNBC.
In the ADAPT-TN neoadjuvant trial, the taxane-carbo arm (12-week nab-paclitaxel
(nab-pac)+carbo) was well tolerable (only 10% SAE-rate), highly effective (pCR,
ypT0/is/ypN0, of 46%) and superior to the gemcitabine (gem)-arm (nab-pac+gem, pCR of
29%). In this study, omission of further chemotherapy was allowed in patients with pCR
after 12 weeks of therapy and was not associated with decreased survival after 3 years
[5] and longer follow up.
Although a standard chemotherapy as well as optimal therapy duration are still to be
defined, several studies are showing a comparable efficacy for longer vs. shorter
adjuvant treatments in TNBC [3], as well as a similar efficacy regarding pCR in
HR-negative (in contrast to HR-positive) early breast cancer (eBC) [26]. Moreover 6 vs. 4
cycles of the same chemotherapy (AC or pac weekly) yielded a similar survival outcome in
eBC despite of HR-status. No such comparison regarding treatment duration is available
for modern antibody-drug conjugates like sacituzumab govitecan (SG).
Therefore, an examination of shorter (12 weeks vs. 18 weeks) regimen as neoadjuvant
treatment appears to be a very promising strategy at least in patients with lower risk
disease or in elderly patients, who do not qualify for polychemotherapy treatments.
In the Keynote-522 trial combination of carboplatin/taxane-anthracycline NACT with the
anti-PD1-antibody pembrolizumab (PEM) has been shown to be associated with a
significantly higher pCR and clinically meaningful better EFS and a trend to better OS.
Noteworthy only patients with more advanced stages IIa-III TNBC were included into the
Keynote-522 trial. Although this effect was independent of clinically assessed nodal
status, there is still some uncertainty on the optimal treatment in patients with
clinical stage I.
In the metastatic setting, SG as a Trop-2-antibody-drug-conjugate has been shown to be
highly efficacious in severely pre-treated patients (all with A/T pre-treated tumours,
most of them carboplatin and 1/3 also anti-PD1 pre-treated) compared to chemotherapy of
investigator´s choice. Treatment with SG was associated with significant longer median
PFS (5.5 vs. 1.7 months) and longer median OS (12.1 vs. 6.7 months). Objective response
was dramatically higher in the SG group vs. treatment by physician´s choice group (34.9
vs. 4.7%), in particular in the 2nd-3rd-line therapy (40% vs. 4%). Moreover, Tropics-02
trial has shown higher efficacy of SG vs. chemotherapy of investigator´s choice in
patients with HR-positive/HER2-negative metastatic breast cancer.
In the neoadjuvant setting, recently presented results from the NeoSTAR trial show a
promising pCR-rate of 30% and RCB 0-1-rate of 36% in TNBC patients with mostly stage
II-III-disease (about 80%) after only 4 cycles of SG.
The following clinical questions are of highest medical need
1. Can 12-18 weeks neoadjuvant treatment with SG alone or in combination with PEM be
associated with comparable pCR-rates (but more favourable safety profile) as shown
for polychemotherapy in TNBC patients at lower relapse risk in historical controls?
2. Can SG-based therapy, as the most promising agent in patients with chemo-resistant
disease, be associated with a such better prognosis (measured by 3-year-iDFS)
compared to historical controls, which would make a randomized phase III-trial
obsolete?
Criteria for eligibility:
Criteria:
Inclusion Criteria:
1. ER + PR negative or low positive (≤10% positive cells in IHC), and HER2 negative
(i.e., IHC 0 - 1+ or IHC 2+ with FISH negative) breast cancer
2. All patients, independent from gender
3. ≥18 years at diagnosis
4. Histologically confirmed unilateral, primary invasive carcinoma of the breast Note:
bilateral, multicentric, or multifocal carcinoma may be included, if there is a
clear target lesion, that is subject to treatment decisions and solely evaluated and
documented for study purposes.
5. Clinical stage I: cT1a-c, cN0 (clinical stage II only, if patient does not qualify
for neoadjuvant polychemotherapy+PEM, e.g., elderly population, per investigator´s
decision)
6. No clinical evidence for distant metastasis (M0)
7. Tumour block available for central pathology review
8. Performance Status ECOG ≤ 1 or KI ≥ 80%
9. Negative pregnancy test (urine or serum) within 7 days prior to registration in
premenopausal patients
10. Written informed consent prior to beginning specific protocol procedures, including
expected cooperation of the patients for the treatment and follow-up, must be
obtained and documented according to the local regulatory requirements
11. The patient must be willing and able to comply with the requirements and
restrictions in this protocol and accessible for treatment and follow-up
12. Laboratory requirements:
- Leucocytes ≥3.5 109/L,
- Neutrophils > 1.5 109/L,
- Platelets ≥100 109/L,
- Haemoglobin ≥10 g/dL,
- AP < 5.0 ULN,
- AST ≤2.5 x ULN,
- ALT ≤2.5 x ULN,
- Total bilirubin ≤1 x ULN,
- Creatinine ≤1.5 × ULN OR clearance ≥30 mL/min for participant with creatinine
levels >1.5 × institutional ULN
13. Clinical assessments:
• LVEF within normal limits of each institution, measured by echocardiography and
normal ECG (within 42 days prior to treatment)
14. The following age-specific requirements apply:
- Women aged <50 years will be considered post-menopausal if they have been
amenorrhoeic for 12 months or more following cessation of exogenous hormonal
treatments and if they have luteinizing hormone (LH) and follicle-stimulating
hormone (FSH) levels in the post-menopausal range for the site.
- Women aged ≥ 50 years will be considered post-menopausal if they have been
amenorrhoeic for 12 months or more following cessation of all exogenous
hormonal treatments.
15. Females on hormone replacement therapy (HRT) and whose menopausal status is in doubt
will be required to use one of the contraception methods outlined for women of
child-bearing potential if they wish to continue their HRT during the study.
Otherwise, they must discontinue HRT to allow confirmation of post-menopausal status
prior to randomization/study enrolment. For most forms of HRT, at least 2-4 weeks
will elapse between the cessation of therapy and the blood draw; this interval
depends on the type and dosage of HRT. Following confirmation of their
post-menopausal status, they can resume use of HRT during the study without use of a
contraceptive method.
16. Female patients of childbearing potential who are sexually active with a
non-sterilized male partner must use at least one highly effective method of
contraception, presented in Table 1 (see Section 4.4.2), from the time of screening
and must agree to continue using such precautions for 7 months after the last dose
of IMP. Not all methods of contraception are highly effective. Female patients must
refrain from breastfeeding while on study and for 7 months after the last dose of
IMP. Complete heterosexual abstinence for the duration of the study and drug washout
period is an acceptable contraceptive method if it is line with the patient's usual
lifestyle (consideration must be made to the duration of the clinical trial);
however, periodic, or occasional abstinence, the rhythm method, and the withdrawal
method are not acceptable.
17. Female patients must not donate, or retrieve for their own use, ova from the time of
randomisation and throughout the study treatment period, and for at least 7 months
after the final study drug administration. They should refrain from breastfeeding
throughout this time. Preservation of ova may be considered prior to enrolment in
this study.
18. A male participant must agree to use a contraception as detailed in Appendix C of
this protocol during the treatment period and for at least 7 months after the last
dose of study treatment and refrain from donating sperm during this period.
Exclusion Criteria:
1. Known hypersensitivity reaction to the compounds or incorporated substances of the
IMPs
2. Prior malignancy with a disease-free survival of < 5 years, except curatively
treated basalioma of the skin or pTis of the cervix uteri
3. Any history of invasive breast cancer
4. Previous or concurrent treatment with cytotoxic agents for any non-oncological
reason unless clarified with sponsor
5. Concurrent treatment with other experimental drugs
6. Participation in another interventional clinical trial with or without any
investigational not marketed drug within 30 days prior to study entry
7. Concurrent pregnancy; patients of childbearing potential or potentially childbearing
partners of male patients must implement a highly effective (less than 1% failure
rate) non-hormonal contraceptive measures during the study treatment
8. Breast feeding woman
9. Reasons indicating risk of poor compliance
10. Patients not able to consent
11. Known polyneuropathy ≥ grade 2
12. Severe and relevant co-morbidity that would interact with the application of
cytotoxic agents or the participation in the study including recovery from major
surgery, autoimmune disease, known psychiatric/substance abuse disorders, acute
cystitis, ischuria, and chronic kidney disease
13. Uncontrolled infection requiring i.v. antibiotics, antivirals, or antifungals
14. History of pneumonitis
15. Active primary immunodeficiency, known human immunodeficiency virus (HIV) infection,
or active hepatitis B or C infection. Patients positive for hepatitis C (HCV)
antibody are eligible only if polymerase chain reaction is negative for HCV RNA.
Patients should be tested for HIV prior to randomisation if required by local
regulations or ethics committee (EC).
16. Have active hepatitis B virus (HBV) or hepatitis C virus (HCV). In patients with a
history of HBV or HCV, patients with detectable viral loads will be excluded.
- Patients who test positive for hepatitis B surface antigen (HBsAg). Patients
who test positive for hepatitis B core antibody (anti-HBc) will require HBV DNA
by quantitative polymerase chain reaction (PCR) for confirmation of active
disease.
- Patients who test positive for HCV antibody will require HCV RNA by
quantitative PCR for confirmation of active disease. Patients with a known
history of HCV or a positive HCV antibody test will not require a HCV antibody
at screening and will only require HCV RNA by quantitative PCR for confirmation
of active disease.
17. Patients who test positive for HIV antibody.
Gender:
Female
Minimum age:
18 Years
Maximum age:
N/A
Healthy volunteers:
No
Start date:
April 2024
Completion date:
September 2029
Lead sponsor:
Agency:
West German Study Group
Agency class:
Other
Collaborator:
Agency:
Gilead Sciences
Agency class:
Industry
Collaborator:
Agency:
Merck Sharp & Dohme LLC
Agency class:
Industry
Source:
West German Study Group
Record processing date:
ClinicalTrials.gov processed this data on November 12, 2024
Source: ClinicalTrials.gov page:
https://clinicaltrials.gov/ct2/show/NCT06081244
